SGLT2 inhibitors reduce adverse kidney and cardiovascular events in patients with advanced diabetic kidney disease: A population-based propensity score-matched cohort study
Main finding · Kidney-related adverse eventsResult — go to the resultOdds ratio 0.48 95 % CI 0.33–0.71Authors' conclusion
SGLT2 inhibitor improved kidney function, glycemic profile, and reduced adverse kidney-related and cardiovascular events in diabetic patients with advanced CKD.
Study context
- Population
- T2D patients at chronic kidney disease (CKD) stage 3B-5, 1 January 2015 through 31 December 2021matched cohort
- Exposure
- SGLT2i vs control
- SGLT2 inhibitorn = 1,450
- Outcome
- Kidney-related adverse events
- Follow-up
- 1 year
Methodological detailspopulation-based, propensity score-matched 1:3
- Population-based
- Propensity score-matched 1:3
Main finding
As reported in the abstract
Odds ratio
0.48
95 % CI 0.33–0.71
P < 0.001
By group
SGLT2ivs Control
OR 0.48 (95 % CI 0.33–0.71); P < 0.001
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Change in eGFR · 1 yeareGFR significantly improved with SGLT2 inhibitor | P < 0.001 |
| Change in HbA1c · 1 yearGreater reduction with SGLT2 inhibitor | P < 0.001 |
| Change in insulin requirement · 1 yearGreater reduction with SGLT2 inhibitor | P < 0.001 |
Safety
| Outcome | Control | P value |
|---|---|---|
| Fungal urinary tract infection · 1 yearSGLT2i vs Control | 0.03 ± 0.23 episodes per year | P < 0.001 |
- Fungal urinary tract infection: SGLT2i 0.08 ± 0.66 episodes per year
Fungal urinary tract infection · 1 year
- SGLT2i use was not associated with other side effects
Original publication
SGLT2 inhibitors reduce adverse kidney and cardiovascular events in patients with advanced diabetic kidney disease: A population-based propensity score-matched cohort study. Diabetes Res Clin Pract. Published 5 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →